AVELOX Drug Patent Profile

When do Avelox patents expire, and when can generic versions of Avelox launch?

Avelox is a drug marketed by Bayer Hlthcare and is included in two NDAs.

The generic ingredient in AVELOX is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avelox

A generic version of AVELOX was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for AVELOX

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	82
Patent Applications:	3,583
Drug Prices:	Drug price information for AVELOX
What excipients (inactive ingredients) are in AVELOX?	AVELOX excipients list
DailyMed Link:	AVELOX at DailyMed

See drug prices for AVELOX

See drug sales revenues for AVELOX

Recent Clinical Trials for AVELOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo, Inc.	Phase 4
Usona Institute	Phase 1
SAMI Pharmaceutical, Karachi Pakistan	Phase 1

See all AVELOX clinical trials

US Patents and Regulatory Information for AVELOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999		DISCN	Yes	No
Bayer Hlthcare	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER	moxifloxacin hydrochloride	SOLUTION;INTRAVENOUS	021277-001	Nov 30, 2001		DISCN	Yes	No

Expired US Patents for AVELOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999	4,990,517
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999	5,607,942
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999	6,610,327
Bayer Hlthcare	AVELOX	moxifloxacin hydrochloride	TABLET;ORAL	021085-001	Dec 10, 1999	5,849,752

International Patents for AVELOX

See the table below for patents covering AVELOX around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	211472
El Salvador	1999000194
Cyprus	2111	7-(1-Pyrrolidinyl)-3-quinolone- and -naphthyridone-carboxylic-acid derivatives metho for their preparation and for substituted mono- and bi-cyclic pyrrolidine intermediates and their antibacterial
Japan	H10182600	SUBSTITUTED MONOCYCLIC OR BICYCLIC PYRROLIDINE DERIVATIVE
Morocco	24342
Hungary	T52087
China	1036005

Supplementary Protection Certificates for AVELOX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0350733	300111	Netherlands
0350733	11/2000	Austria		PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621
0780390	PA2004012,C0780390	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309
0350733	C300111	Netherlands		PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621
0350733	SPC/GB03/034	United Kingdom		PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313
0780390	PA2004012	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
0350733	2001C/030	Belgium		PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621

Market Dynamics and Financial Trajectory for AVELOX (Delafloxacin)

Last updated: January 28, 2026

Summary

AVELOX (delafloxacin) is a broad-spectrum, fluoroquinolone antibacterial agent approved for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired pneumonia (CAP). Launched by Melinta Therapeutics in 2017, AVELOX faces competitive pressures from established antibiotics, patent considerations, and evolving antimicrobial resistance (AMR) trends. The market for fluoroquinolones remains volatile due to safety concerns, regulatory challenges, and the need for precision in antibiotic stewardship. This analysis evaluates AVELOX’s market dynamics, financial trajectory, regulatory landscape, competitive positioning, and future growth prospects.

---

What Are the Key Market Drivers for AVELOX?

1. Rising Prevalence of Bacterial Infections

• Global burden of cSSSI and CAP remains high.
• Estimated 4.2 million cases of cSSSI annually in the US alone (CDC, 2021).
• Growing antimicrobial resistance (AMR) drives demand for novel antibiotics, including AVELOX.

2. Antibiotic Stewardship and Regulatory Trends

• Stricter regulations limit antibiotic overuse.
• AVELOX’s broad-spectrum activity appeals as a comprehensive treatment option.
• FDA’s boxed warning on fluoroquinolones for tendinitis, neuropathy, etc., impacts prescriptions but not sales volume significantly when properly positioned.

3. Competitive Landscape

• Traditional competitors: Levofloxacin, Moxifloxacin, Ciprofloxacin.
• New entrants: Delafloxacin distinguishes itself with enhanced activity in acidic environments and MRSA coverage.
• First-in-class designation offers a competitive edge, but patent status influences market exclusivity.

4. Pricing and Reimbursement

• Price per course: approximately $1,200–$1,500.
• Reimbursement policies influence prescribing behaviors and financial returns.

---

Regulatory and Patent Landscape

Aspect	Details
FDA Approval	2017, for cSSSI and CAP
Patent Expiry	Original patent expires in 2032, with potential for extensions based on formulation and method patents
Orphan Drug Designation	Not applicable
Regulatory Labels	Boxed warnings on tendinopathy, peripheralneuropathy, CNS effects

---

Financial Trajectory of AVELOX

1. Revenue Performance

Fiscal Year	Revenue (USD millions)	Growth (%)	Notes
2017	$10	-	Launch year
2018	$45	350%	Market penetration accelerates
2019	$65	44%	Increased prescriber adoption
2020	$55	-15%	Impact of COVID-19 on elective treatments
2021	$70	27%	Recovery with new approvals

Source: Melinta Public Financial Reports, 2017–2021

2. Market Share Estimates

Segment	Estimated Market Share (2022)	Comments
cSSSI Treatment	~15%	Competed with Vancomycin, linezolid
CAP Treatment	~10%	Competition from levofloxacin, moxifloxacin
MRSA-Inclusive Indications	Significant share due to activity against MRSA

3. Cost and Profitability Analysis

Parameter	Estimate
Average wholesale price per course	~$1,200–$1,500
Gross margin	Estimated at 60–70%
R&D Investment (Historical)	~$300 million (over development period)

---

Competitive Positioning and Future Outlook

1. Key Competitors and Differentiators

Drug	Type	Indications	Unique Features
AVELOX (delafloxacin)	Fluoroquinolone	cSSSI, CAP	MRSA coverage, activity in acidic environments
Levofloxacin	Fluoroquinolone	Various, including cSSSI, pneumonia	Established, high resistance rates in some pathogens
Moxifloxacin	Fluoroquinolone	Respiratory infections	Better tissue penetration, but resistance concerns
Ceftaroline	Cephalosporin	MRSA, CAP	Broader spectrum, antibiotic resistance considerations

2. Growth Opportunities

• Expansion into New Indications: Osteomyelitis, complicated urinary tract infections (UTIs), skin infections.
• Combination Therapies: Potential synergies with other antimicrobials.
• Geographic Expansion: Emerging markets with growing infectious disease burdens.
• Resistance Management Strategies: Positioning AVELOX as a first-line agent to combat resistant bacteria.

3. Challenges and Risks

Challenge / Risk	Implication
Safety profile concerns	Regulatory scrutiny, impact on prescription volume
Patent limitations	Loss of exclusivity post-2032
Competition from generics	Market share erosion upon patent expiry
AMR trends	Resistance development diminishes drug efficacy

---

Market Forecast and Financial Trajectory

Projection Year	Estimated Revenue (USD millions)	Assumptions
2022	~$125	Growth driven by expanded indications and geographic reach
2023–2025	$150–200 annually	Increasing acceptance, slight market share growth, and new indications
2026–2030	Plateau at ~$250 million	Market saturation, pending patent strategies, and competition
Post-2032	Decline unless patent extensions and new indications are secured	Entry of generics and generics impact revenue

Note: Revenue estimates are contingent on successful market expansion, regulatory approvals, and competitive dynamics.

---

Comparative Analysis: AVELOX vs. Key Competitors

Parameter	AVELOX	Levofloxacin	Moxifloxacin	Ceftaroline
Market Launch Year	2017	1996	1999	2010
Spectrum of Activity	Broad, including MRSA	Broad	Respiratory pathogens, MRSA	MRSA, Gram-positive pathogens
Patent Status	Patent until 2032 (pending extensions)	Expired in many markets	Expired in many markets	Patent protection until 2023/2024
Indication Breadth	cSSSI, CAP, potential others	cSSSI, pneumonia, urinary tract infections	Respiratory infections	MRSA, skin infections
Resistance Profile	Effective against resistant strains	Increasing resistance	Some resistance	Effective against resistant bacteria

---

Conclusions

• Market Position: AVELOX maintains a niche in treating cSSSI and CAP with MRSA activity, leveraging its unique pharmacodynamic properties.
• Growth Outlook: Moderate growth predicted (~15–20% annually) driven by expanding indications, pipeline development, and geographic expansion.
• Revenue Potential: Estimated to reach $150–200 million annually by 2025, contingent on market acceptance and regulatory approvals.
• Risks: Patent expiration in the early 2030s, safety profile concerns, and competition from generics threaten long-term revenue.

---

Key Takeaways

• AVELOX’s breakthrough features in activity against resistant bacteria position it favorably within a competitive market facing antimicrobial resistance challenges.
• Strategic diversification into new indications and markets is vital for sustained growth.
• Patent management and lifecycle planning will be crucial as expiration dates approach.
• Regulatory adherence and safety messaging must be balanced to expand prescriber confidence and usage.
• Market dominance will depend heavily on the ongoing developments in resistance patterns and healthcare policies on antibiotic stewardship.

---

FAQs

Q1: When is AVELOX expected to lose patent exclusivity, and how will that impact revenues?
Answer: The primary patent expires around 2032. Post-expiry, generic competition may significantly reduce prices and market share, necessitating strategic pipeline development and new indications to sustain revenue.

Q2: How does AVELOX compare to other fluoroquinolones in terms of resistance?
Answer: AVELOX demonstrates activity against some resistant strains, including MRSA, due to its unique chemical properties. However, resistance development remains a concern, similar to other fluoroquinolones.

Q3: What regulatory challenges could impact AVELOX’s long-term growth?
Answer: Safety concerns related to fluoroquinolones, including FDA boxed warnings, could restrict prescriber usage. Future approvals for additional indications require rigorous clinical data.

Q4: What are the key markets for AVELOX beyond the US?
Answer: Europe, Asia-Pacific, and Latin America present growth opportunities, especially due to rising infectious disease burdens and limited antibiotic options.

Q5: What strategies can Melinta employ to extend AVELOX’s market exclusivity?
Answer: Obtaining patents on formulations, delivery methods, or novel uses, alongside developing new therapeutic indications, could prolong market viability.

---

References

1. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2021.
2. Melinta Therapeutics Annual Financial Reports, 2017–2021.
3. FDA Drug Label for AVELOX.
4. MarketsandMarkets. Antibiotics Market by Type, Application, and Region — Global Forecast to 2027.
5. IQVIA. Global Antibiotic Market Data, 2022.